OLMA vs. NAGE, AUPH, ELVN, ABCL, WVE, VERV, PAHC, AKBA, COLL, and NTLA
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Niagen Bioscience (NAGE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), WAVE Life Sciences (WVE), Verve Therapeutics (VERV), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.
Olema Pharmaceuticals vs. Its Competitors
Olema Pharmaceuticals (NASDAQ:OLMA) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.
Olema Pharmaceuticals has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500.
Niagen Bioscience has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 16.4% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 9.4% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Niagen Bioscience had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 6 mentions for Niagen Bioscience and 1 mentions for Olema Pharmaceuticals. Niagen Bioscience's average media sentiment score of 0.33 beat Olema Pharmaceuticals' score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.
Niagen Bioscience has a net margin of 13.07% compared to Olema Pharmaceuticals' net margin of 0.00%. Niagen Bioscience's return on equity of 19.06% beat Olema Pharmaceuticals' return on equity.
Olema Pharmaceuticals currently has a consensus target price of $24.50, indicating a potential upside of 456.82%. Niagen Bioscience has a consensus target price of $19.50, indicating a potential upside of 53.42%. Given Olema Pharmaceuticals' higher possible upside, equities analysts clearly believe Olema Pharmaceuticals is more favorable than Niagen Bioscience.
Summary
Niagen Bioscience beats Olema Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:OLMA) was last updated on 7/3/2025 by MarketBeat.com Staff
Free OLMA Stock Alerts